Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1:: 2003 recommendations of an international AIDS Society-USA panel

被引：398

作者：

Hirsch, MS

Brun-Vézinet, F

Clotet, B

Conway, B

Kuritzkes, DR

D'Aquila, RT

Demeter, LM

Hammer, SM

Johnson, VA

Loveday, C

Mellors, JW

Jacobsen, DM

Richman, DD

机构：

[1] Harvard Univ, Sch Med, Boston, MA USA

[2] Brigham & Womens Hosp, Boston, MA 02115 USA

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Univ Rochester, New York, NY USA

[5] Columbia Univ, Coll Phys & Surg, New York, NY USA

[6] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA

[7] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA

[8] Univ Pittsburgh, Pittsburgh, PA USA

[9] Vet Affairs Med Ctr, Pittsburgh, PA USA

[10] Int AIDS Soc USA, San Francisco, CA USA

[11] Univ Calif San Diego, La Jolla, CA 92093 USA

[12] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA

[13] Hop Bichat Claude Bernard, F-75877 Paris 18, France

[14] Hosp Badalona Germans Trias & Pujol, HIV Unit, Barcelona, Spain

[15] Hosp Badalona Germans Trias & Pujol, Fdn IrsiCAIXA, Barcelona, Spain

[16] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 37卷 / 01期

关键词：

D O I：

10.1086/375597

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel of physicians and scientists with expertise in antiretroviral drug management, HIV-1 drug resistance, and patient care to provide updated recommendations for HIV-1 resistance testing. Published data and presentations at scientific conferences, as well as strength of the evidence, were considered. Properly used resistance testing can improve virological outcome among HIV-infected individuals. Resistance testing is recommended in cases of acute or recent HIV infection, for certain patients who have been infected as long as 2 years or more prior to initiating therapy, in cases of antiretroviral failure, and during pregnancy. Limitations of resistance testing remain, and more study is needed to refine optimal use and interpretation.

引用

页码：113 / 128

页数：16

共 169 条

[1] Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture [J].